Biocryst Pharmaceuticals (BCRX) Current Deferred Tax Assets (2010 - 2019)

Biocryst Pharmaceuticals has reported Current Deferred Tax Assets for 10 years, with the latest figure at $9000.0 in Q1 2019.

• For the quarter ending Q1 2019, Current Deferred Tax Assets fell 94.08% year-over-year to $9000.0; the trailing twelve-month figure through Mar 2019 stood at $9000.0 (down 94.08% YoY), and the FY2018 full-year result was $9000.0, down 95.71% from the prior year.
• Current Deferred Tax Assets for Q1 2019 stood at $9000.0, roughly flat from $9000.0 in the prior quarter.
• The five-year high for Current Deferred Tax Assets was $218000.0 in Q3 2017, with the low at $8000.0 in Q3 2018.
• Historically, Current Deferred Tax Assets has averaged $88000.0 across 5 years, with a median of $88000.0 in 2015.
• Annual changes were most pronounced in 2017 — Current Deferred Tax Assets jumped 147.06% — and 2018, when it plunged 96.33%.
• Biocryst Pharmaceuticals' Current Deferred Tax Assets stood at $90000.0 in 2015, then dropped by 5.56% to $85000.0 in 2016, then jumped by 147.06% to $210000.0 in 2017, then sank by 95.71% to $9000.0 in 2018, then changed by 0.0% to $9000.0 in 2019.
• The last three Current Deferred Tax Assets figures came in at $9000.0 (Q1 2019), $9000.0 (Q4 2018), and $8000.0 (Q3 2018), per Business Quant data.